Samsung Bioepis names Kyung-Ah Kim president/CEO
Samsung Bioepis has appointed Kyung-Ah Kim president and CEO.
Kim, who has been serving as executive vice president and development division leader will succeed Christopher Hansung Ko, who has been appointed to lead the Samsung future business division.
Kim, a veteran scientist with more than 20 years of experience in biologic development, has been serving as development division leader since December 2021, overseeing all of Samsung Bioepis’ product development cycle across various therapeutic areas.
[Read more: AAM report: Generics, biosimilars generate $445B in savings]
Since joining Samsung Bioepis in December 2015, she has been serving various leadership posts within the development division.
Prior to joining Samsung Bioepis, Kim worked as principal scientist and later as vice president at Samsung Advanced Institute of Technology leading the biotherapeutics group focusing on development of antibody therapeutics targeting oncology.
Before joining SAIT, she worked as a scientist/head of cell biology at multiple biopharmaceutical companies, leading various projects on development of therapeutic agents, including genetic sequencing and profiling, development of drug screening assays, pre-clinical assessment, pharmacological assessment and functional assessment of antibodies.
[Read more: Samsung Bioepis releases 2024 U.S. biosimilar market report]
Kim holds a Ph.D, in neurotoxicology from The Johns Hopkins University where she established signal transduction pathway, specifically in the learning impairment caused by genetic perturbation in lead poisoning.